Hanmi Pharmaceutical has obtained U.S. approval for its neutropenia treatment Rolontis, opening a new chapter in its R&D history. It is the first drug that Hanmi has succeeded in commercializing in the global market.Spectrum Pharmaceuticals, a U.S. partner to which Hanmi Pharmaceutical licensed out
Short selling in the South Korean stock market is increasing along with the possibility of another economic recession. Short sellers are targeting overvalued stocks and those more vulnerable to recession risks in particular.The Korea Exchange announced on Sept. 1 that short selling in the market tot
SK Inc. and SK Innovation (collectively, “SK”) invest in a next-generation small modular reactor (SMR) developer in the United States, stepping up their efforts to reduce global carbon emission. The investment is likely to provide a boost to SK Group’s strategy for the early achievement of net-zero
In the first half of 2022, Korea's health industry exports such as pharmaceuticals, medical devices, and cosmetics reached an all-time high on a semiannual basis. Export growth was driven by diagnostic reagents and COVID-19 vaccines.The industry's exports totaled US$13.35 billion in the firs
SK Group chairman Chey Tae-won held a video conference with U.S. President Joe Biden on July 26 and said his group would make an additional investment of US$22 billion (28.8 trillion won) in the United States.SK Group has already announced it would invest US$7 billion (9.1 trillion won) in the Unite
Samsung Biologics is aiming to become the world’s No. 1 contract design and manufacturing organization (CDMO) by establishing a second biotech campus in Songdo International City, Incheon.The company announced on July 18 that it has signed a contract with the Incheon Metropolitan Government to acqui
Samsung Group announced on May 24 an expansion of its investment commitment with plans to spend a total of 450 trillion won over five years until 2026, to accelerate growth in semiconductors, biopharmaceuticals and other next-generation technologies.With the investment, which represents a more than
Samsung Biologics’ market capitalization has surpassed that of Lonza, the world’s largest biopharmaceutical contract manufacturing organization (CMO) company.Samsung Biologics’ market cap stood at 59.43 trillion won as of April 28, exceeding the 42.85 billion Swiss francs (about 55.62 trillion won)
Kolon Life Science has licensed out its osteoarthritis cell gene treatment TG-C, also known as Invossa, to a new biotech company in Singapore in a deal worth up to 720 billion won.The company announced on April 13 that it has signed a 723.4 billion won (US$587.18 million) technology export contract
HanAll Biopharma and Daewoong Pharmaceutical announced on April 11 an expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio’s continued development of a hig
The authors are analysts of Shinhan Investment Corp. They can be reached at sh.kim@shinhan.com and mintz95@shinhan.com, respectively. -- Ed. Plans for share buyback and retirementSK announced plans for annual share buyback equivalent to 1% or more of its market cap in a bid to enhance enterprise val
Dong-A ST, a prescription drug manufacturer affiliated with Dong-A Socio Group, has topped 1.3 trillion won in cumulative exports since 2011.The company announced on March 7 that it set a new export record of 140 billion won in 2021. Export growth was led by biopharmaceuticals. Sales of Eporon, a tr
Incheon City Mayor Park Nam-chun took office in July 2018. Since then, the city has accelerated its growth as a hub of Korea's future industries. The following is a recent interview with him, whose term is scheduled to end on June 30. – Ed.What would you pick as your best achievements as the may
SK Inc., the strategic investment holding company of SK Group, will be paying out the largest ever dividends to its shareholders.The company's board of directors approved its plan to pay a year-end dividend of 6,500 won per share on Feb. 9. Accordingly, SK Inc. shareholders will receive an annua
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In January, NYSE pharmaceuticals indices tumbled, with both large caps and small caps being weighed upon by adverse macro conditions. However, the coupling between Covid-19 sentiment and biotech appe
Samsung Biologics announced its sustainable growth plan for this year at the 2022 Annual J.P. Morgan Healthcare Conference, which was held virtually from Jan. 10-13 with leaders from major pharmaceutical and biopharmaceutical companies and key investors.During the main track presentation on Jan. 12
SK Group has entered the U.S. cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) market. It has entered both the European and U.S. CGT CDMO markets.SK Inc., the group's holding company, announced on Jan. 9 that it has become the second-largest shareholder of C
SK Biopharmaceuticals announced on Dec. 23 that it has licensed out Cenobamate technology to Endo International, a specialty pharmaceutical company based in Dublin, Ireland.Cenobamate is a medication used for the treatment of partial-onset seizures, a kind of epilepsy. It is sold under the brand nam
SK Bioscience, a company that develops vaccines and produces biopharmaceuticals on a contract basis, has been found to be the best-performing IPO in the world in 2021.According to a report by Bloomberg, SK Bioscience is the top gainer among the initial public offerings that raised more than $1 billi
SK Group chairman Chey Tae-won said that his group has no plan to build a semiconductor manufacturing plant in the United States, adding, however, that it is studying preconditions for such an investment.The U.S. is a huge market but human resources and cost are problems, Chey said in an interview w